PHG vs NNNN Stock Comparison

Koninklijke Philips and Anbio Biotechnology Prices as of Oct 26, 2026 Peers: Industry group
PHG Koninklijke Philips Nv
$26.56 +6.4% 1M -7.9% 1Y
Market cap
$25.07B
P/E
13.6x
Revenue (TTM)
$20.60B
Div. yield
–
Diagnostic Equipment Healthcare
4 wins
NNNN Anbio Biotechnology
$3.70 -41.3% 1M -83.9% 1Y
Market cap
$166.83M
P/E
25.2x
Revenue (TTM)
—
Div. yield
–
Diagnostic Equipment Healthcare

Head to Head

4 decided of 12

Koninklijke Philips leads on 4 of the 12 questions below (Koninklijke Philips 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionPHGNNNNLeader
Larger companyMarket capitalisation $25.07B $166.83M PHG
Cheaper on earningsLower P/E, profitable companies only 13.6x 25.2x PHG
Cheaper on forward earningsLower price / next fiscal year consensus EPS 13.4x — –
Faster revenue growthRevenue growth, trailing twelve months +6.1% — –
More profitableNet margin, trailing twelve months 8.9% — –
Better return on capitalReturn on invested capital 11.5% — –
Less leveragedLower net debt / EBITDA 1.8x — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -7.9% -83.9% PHG
Better 5-year returnAnnualised price return, 5 years -10.8%/yr — –
Less volatileAnnualised volatility, 1 year 28.8% 136.2% PHG
Higher overall scoreMean of the five percentile scores vs peers 80/100 — –

Percentile Scorecard

PHGNNNN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisPHGNNNN
Valuation 98 #6 of 228 19 #185 of 228
Growth 96 #11 of 221 –
Profitability 96 #10 of 208 –
Financial Health 31 #166 of 239 100 #1 of 239
Shareholder Returns 79 #29 of 137 –
Overall 80 –
  • PHG ranked among 248 companies in Medical Devices and Diagnostics
  • NNNN ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodPHGNNNNSPY
1 month +6.4%-41.3% -0.8%
3 months +6.2%-63.7% +3.5%
6 months -3.6%-86.6% +7.0%
Year to date -1.9%-87.7% +12.2%
1 year -7.9%-83.9% +13.0%
3 years +43.6%— +86.3%
3 years, per year +12.8%— +23.1%
5 years -43.6%— +68.6%
5 years, per year -10.8%— +11.0%
10 years -11.6%— +258.0%
10 years, per year -1.2%— +13.6%

Risk

MeasurePHGNNNNSPY
Volatility, 1Y 28.8%136.2% 12.7%
Downside volatility, 1Y 28.8%136.2% 12.7%
Beta vs S&P 500, 1Y 0.810.26 1.00
Return / volatility, 1Y -0.27-0.62 1.02
Max drawdown, 5Y -75.6%-94.0% -25.4%
From 52-week high -19.3%-91.0% -1.8%
52-week high $32.91$41.11 $779.14
52-week low $23.81$3.13 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultiplePHGNNNN
P/E now vs peer median 13.7xmedian 30.6x 25.2xmedian 30.6x
P/S now vs peer median 1.2xmedian 3.0x 61.6xmedian 3.0x
EV/EBITDA now vs peer median 8.1xmedian 17.5x —median 17.5x
P/FCF now vs peer median 5.9xmedian 23.3x -79.0xmedian 23.3x
P/B now vs peer median 2.0xmedian 2.4x 17.7xmedian 2.4x
PEG now vs peer median 0.32median 0.87 —median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsPHGNNNN
Revenue $20.60B –
Gross profit $16.03B –
Operating income $2.65B –
Net income $1.39B –
Free cash flow $4.34B –
R&D $2.00B –
EPS (diluted) $1.91 –
Cash & equivalents $2.04B $7.77M
Total debt $9.51B –
Shares (diluted) 962.50M 43.67M
Enterprise value $14.18B $120.05M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricPHGNNNN
P/E 13.7x 25.2x
P/FCF 5.9x -79.0x
P/Operating cash flow 9.6x –
P/S 1.2x 61.6x
P/B 2.0x 17.7x
P/Tangible book 2.5x 17.7x
EV/EBITDA 8.1x –
EV/EBIT 12.4x –
EV/Revenue 1.6x –
EV/FCF 7.6x –
EV/Operating cash flow 12.4x –
PEG (3Y EPS CAGR) 0.32 –

Growth

14 metrics
MetricPHGNNNN
Revenue growth (1Y) 6.1% –
Revenue CAGR (3Y) 2.3% –
Gross profit growth (1Y) 82.4% –
Gross profit CAGR (3Y) 6.7% –
Operating income growth (1Y) 121.3% –
Operating income CAGR (3Y) 52.0% –
Net income growth (1Y) 293.5% –
Net income CAGR (3Y) 35.6% –
EPS growth (1Y) 539.4% –
EPS CAGR (3Y) 42.2% –
Operating cash flow growth (1Y) 116.7% –
Operating cash flow CAGR (3Y) 53.6% –
Free cash flow growth (1Y) 54.2% –
Free cash flow CAGR (3Y) 45.6% –

Profitability

14 metrics
MetricPHGNNNN
Gross margin 77.8% –
EBITDA margin 19.8% –
Operating margin 12.9% –
Pretax margin 11.9% –
Net margin 8.9% –
FCF margin 21.1% –
Operating cash flow margin 12.9% –
Return on equity 12.7% –
Return on assets 5.4% –
Return on invested capital 11.5% –
Return on capital employed 11.8% –
Asset turnover 0.7x –
Cash conversion (OCF / net income) 1.9x –
Stock comp / revenue 0.7% –

Financial Health

11 metrics
MetricPHGNNNN
Debt / assets 31.2% –
Debt / equity 0.7x –
Net debt / EBITDA 1.8x –
Debt / FCF 2.2x –
Liabilities / assets 57.1% 0.3%
Equity / assets 42.9% 99.7%
Interest coverage 6.2x –
Current ratio 1.3x 344.3x
Quick ratio 0.7x 177.1x
Cash ratio 0.2x 135.5x
Altman Z-score – –

Shareholder Returns

7 metrics
MetricPHGNNNN
Dividend yield 3.7% –
Net buyback yield -0.5% –
Shareholder yield 3.3% –
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusPHGNNNN
Forward P/E 13.4xFY2026 –
EPS, next fiscal year $1.98FY2026 –
EPS growth, next FY +6.5%FY2026 –
EPS growth, the year after -10.1% –
Revenue, next fiscal year $21.63BFY2026 –
Revenue growth, next FY +1.8%FY2026 –
Revenue growth, the year after -8.2% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersPHGNNNN
Held by institutions 5.4% 0.0%
Institutions holding 363 12
Change in shares held, QoQ +0.8% +39.8%
Institutions buying 266 8
Institutions selling 76 3
Buyers to sellers 3.50 2.67

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

PHGNNNN
PHG 1.00 0.07
NNNN 0.07 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, PHG and NNNN?

Koninklijke Philips (PHG) is the largest by market capitalisation: Koninklijke Philips (PHG) $25.07B, Anbio Biotechnology (NNNN) $166.83M.

Which stock is cheaper, PHG and NNNN?

Koninklijke Philips (PHG) trades on the lowest price-to-earnings ratio (Koninklijke Philips (PHG) 13.6x, Anbio Biotechnology (NNNN) 25.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which stock has performed better?

Over the past year Koninklijke Philips (PHG) returned the most: Koninklijke Philips (PHG) -7.9%, Anbio Biotechnology (NNNN) -83.9%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (Koninklijke Philips (PHG) 28.8%, Anbio Biotechnology (NNNN) 136.2%). Volatility measures how widely the price swings, not the risk of the business.

Do PHG and NNNN move together?

Their daily returns over the past year have a correlation of 0.07, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, PHG and NNNN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.